Engineered gene networks enable non-genetic drug resistance and enhanced cellular robustness

by Brendan Camellato, Ian J. Roney, Afnan Azizi, Daniel Charlebois, Daniel Charlebois, Mads Kaern, Mads Kaern
Published 2019-10-01

33 Experiences and expectations of participants completing HIV cure-focused clinical trials

by J.H. McMahon, J.S.Y. Lau, M. Hagenauer, J. Roney, T.A. Rasmussen, J.H. Elliott, S.R. Lewin
Published 2017-07-01

Erythroid-specific expression of β-globin from Sleeping Beauty-transduced human hematopoietic progenitor cells.

by Lucas M Sjeklocha, Chang-Won Park, Phillip Y-P Wong, Mark J Roney, John D Belcher, Dan S Kaufman, Gregory M Vercellotti, Robert P Hebbel, Clifford J Steer
Published 2011-01-01

Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial

by A. J. Wade, J. S. Doyle, E. Gane, C. Stedman, B. Draper, D. Iser, S. K. Roberts, W. Kemp, D. Petrie, N. Scott, P. Higgs, P. A. Agius, J. Roney, L. Stothers, A. J. Thompson, M. E. Hellard
Published 2018-07-01

O5 Hepatitis C elimination in HIV/HCV co-infection through HCV treatment in primary care is feasible and highly effective

by J.S. Doyle, A.L. Bowring, J. Cutts, J. Roney, D.M. Iser, J. Sasadeusz, M. O’Reilly, C. Fairley, E. Gane, J. Hoy, G.V. Matthews, N. Medland, R. Moore, M. Prins, M. Stoové, B.K. Tee, M.E. Hellard
Published 2017-08-01